USV Biologics Division
Mumbai, India· Est.
Indian pharma company delivering generics and biosimilars with a strong API manufacturing base.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Indian pharma company delivering generics and biosimilars with a strong API manufacturing base.
DiabetesCardiovascularGeneral Medicine
Technology Platform
High‑volume chemical synthesis for small‑molecule APIs combined with recombinant DNA and cell‑culture platforms for biosimilar development.
Opportunities
Expansion of biosimilar portfolio and increased API capacity position USV to capture growing demand in emerging markets and secure contracts with multinational pharma partners.
Risk Factors
Regulatory hurdles in new geographies, intense price competition from established generics manufacturers, and potential supply‑chain disruptions.
Competitive Landscape
USV competes with Indian giants such as Sun Pharma, Dr. Reddy's, and Cipla, differentiating through its integrated API‑to‑biosimilar platform and expanding global footprint.